Vilin Bio Med Ltd.

VILINBIO.NS · National Stock Exchange of India · INR

54,55INR

0,00 (0,00 %)Stand 8. Nov., 8:59

Vortag 54,55

Kennzahlen

Eröffnung
54,55
Vortag
54,55
Tagesspanne
54,55 – 54,55
52 Wochen
18,95 – 60,95
Volumen
2000
Ø Volumen
20.800
Börsenwert
760,97 Mio. INR
KGV
–
Gewinn je Aktie (TTM)
–
Dividendenrendite
–
Beta
0,6
Nächste Zahlen
–

Finanzen

Gerade nicht verfügbar.

Bewertung

Gerade nicht verfügbar.

Analysten

Einstufungen

Gerade nicht verfügbar.

Kursziel

Gerade nicht verfügbar.

Quartalszahlen

Gewinn je Aktie · Erwartet
Gewinn je Aktie · Tatsächlich
Abweichung
Umsatz · Tatsächlich

Dividenden und Splits

Keine Dividenden gezahlt.

Aktiensplits

–

Eigentümer

Institutionen

Gerade nicht verfügbar.

Insider-Geschäfte

–

Vergleichbare Unternehmen

–

Über das Unternehmen

Vilin Bio Med Ltd. is a domestic pharmaceutical company primarily engaged in the manufacturing and trading of pharmaceutical products, with a focus on generic formulations across various therapeutic segments. The company produces pharmaceutical formulations such as oral liquids, dry syrups, sachets, external preparations, beta and non-beta lactam tablets and capsules, and nutritional food supplements. These products address therapeutic areas including anti-infectives, analgesics, cardiovascular, musculoskeletal, antibiotic, central nervous system, alimentary system, genito-urinary tract, respiratory system, anti-allergic, and anti-diabetic conditions. Vilin Bio Med also engages in contract manufacturing and the distribution of its own branded generics, supplying products in bulk to pharmaceutical manufacturers, marketers, and traders. Beyond pharmaceuticals, the company offers a range of cosmetics, including products for baby care, skin care, oral care, and hair care, such as serums, oils, lotions, creams, cleansers, moisturizers, and masks. The primary target market for Vilin Bio Med is the domestic Indian market, which generates over 90% of its revenue, though it also has international operations and a U.S. subsidiary for marketing and distribution in the United States, alongside a presence in GCC, Africa, EU, and Asia.

CEO
adamakanti Madhu S. Reddy
Mitarbeitende
14
Hauptsitz
Secunderabad, TS, IN
Sektor
Healthcare
Branche
Medical - Pharmaceuticals
Börsengang
30. Juni 2023

Nachrichten

Gerade keine Nachrichten zu diesem Unternehmen.

Kurse mindestens 15 Minuten verzögert. Daten: Financial Modeling Prep. Keine Anlageberatung.